Nasdaq

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

NATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development ...
FierceBiotech

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...
Nasdaq

ModeX Therapeutics Establishes Scientific Advisory Board to Enhance Development of Multispecific Antibodies for Complex Diseases

ModeX Therapeutics Inc., an OPKO Health company, announced the formation of a Scientific Advisory Board to support the development of its immunology and oncology pipeline, which includes ...
Seeking Alpha

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health (OPK) company, today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly ...
Seeking Alpha

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health (OPK) company, today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical ...